Literature DB >> 8068599

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation.

F Kronenberg1, P König, K Lhotta, D Ofner, C Sandholzer, R Margreiter, E Dosch, G Utermann, H Dieplinger.   

Abstract

High lipoprotein(a) [Lp(a)] plasma concentrations are an independent risk factor for atherosclerosis. In the general population, Lp(a) levels are primarily determined by allelic variation at the apolipoprotein(a) [apo(a)] gene locus. Apo(a) isoforms of various sizes are associated with different Lp(a) concentrations. Patients with end-stage renal disease (ESRD) have elevated plasma concentrations of Lp(a), which are not explained by the size variation at the apo(a) gene locus. To further investigate the origin of the elevated Lp(a) plasma concentrations, we examined Lp(a) concentrations and apo(a) phenotypes in 154 ESRD patients undergoing renal transplantation. In a prospective longitudinal study we observed a rapid normalization of Lp(a) levels from an average concentration of 25.9 +/- 28.7 mg/dL before to 17.9 +/- 25.5 mg/dL 3 weeks after renal transplantation (P < .0001). Only patients with high-molecular-weight phenotypes had a significant decrease in Lp(a) plasma concentrations. This study demonstrates the nongenetic origin of elevated Lp(a) concentrations in ESRD patients, which is obviously caused by the disease. It further confirms a phenotype-associated elevation of Lp(a) concentrations in ESRD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068599     DOI: 10.1161/01.atv.14.9.1399

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  9 in total

Review 1.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 2.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

3.  Enigmatic role of lipoprotein(a) in cardiovascular disease.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Lars Berglund
Journal:  Clin Transl Sci       Date:  2010-12       Impact factor: 4.689

Review 4.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 5.  Lipoprotein (a): When to Measure and How to Treat?

Authors:  David Rhainds; Mathieu R Brodeur; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2021-07-08       Impact factor: 5.113

6.  Effects of renal replacement therapy on plasma lipoprotein(a) levels.

Authors:  Sylvia Rosas; Marshall Joffe; Megan Wolfe; Kenneth Brayman; Daniel J Rader
Journal:  Am J Nephrol       Date:  2007-12-05       Impact factor: 3.754

Review 7.  Non-genetic influences on lipoprotein(a) concentrations.

Authors:  Byambaa Enkhmaa; Lars Berglund
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

8.  Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis.

Authors:  J K Gambhir; O P Kalra; A Khaira; H Kaur
Journal:  Indian J Nephrol       Date:  2013-01

Review 9.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.